P&G Spinout Spins Off Another Company, While Looking To Partner Mid-Stage Oral Anemia Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Akebia will sell off, partner or possibly bring AKB-6548 – thought to be a safer erythropoietin stimulator than currently available injectables – through Phase III, while its spinout, Aerpio, will focus on clinical development of candidates for diabetic macular edema and inflammatory bowel disease.